Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Immediate Effects of External Trigeminal Nerve Stimulation on Motor Dysfunction in Parkinson's Disease

2026. június 14. frissítette: Zhengli Di

Parkinson's disease (PD), the most common movement disorder, is characterized by motor symptoms including tremor, rigidity, bradykinesia, and postural instability. These symptoms substantially impair quality of life and increase the risk of falls, disability, and accidental injury, representing a major therapeutic challenge.

External trigeminal nerve stimulation (eTNS), a non-invasive neuromodulation technique, has shown promising potential in PD and other movement disorders. A clinical study published in 2017 suggested that trigeminal nerve stimulation may contribute to the alleviation of motor symptoms in patients with PD. In 2023, the U.S. Food and Drug Administration cleared the Portable Neuromodulation Stimulator (PoNS) as an adjunctive treatment for gait impairment caused by multiple sclerosis; the lingual nerve is a branch of the mandibular division of the trigeminal nerve. In the same year, experimental evidence showed that trigeminal nerve stimulation could activate intracranial dopaminergic neurons and modulate dopamine release in mice. These findings suggest substantial potential for eTNS in modulating motor dysfunction in PD, although high-level clinical evidence remains lacking.

This randomized, within-subject study will evaluate the immediate effects of eTNS at different stimulation frequencies on motor dysfunction in patients with PD. Gait parameters will be quantitatively assessed using the IDEEA gait system, together with the MDS-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III), Tinetti Gait Scale, and Hoehn and Yahr Scale.

This within-subject study comprises three 20-min stimulation conditions: 120-Hz eTNS, 40-Hz eTNS, and sham stimulation. Each patient with Parkinson's disease will complete all conditions in a single session in randomized order. Instrumented gait analysis, together with motor and gait rating scales, will be used to quantify immediate post-stimulation changes in gait and motor function relative to baseline.

A tanulmány áttekintése

Állapot

Még nincs toborzás

Körülmények

Beavatkozás / kezelés

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

30

Fázis

  • Nem alkalmazható

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Tanulmányi helyek

  • Kína
    • Shaanxi
      • Xi'an, Shaanxi, Kína, 710000
        • Xi'an Central Hospital, Department of Neurology
        • Kapcsolatba lépni:

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

  • Felnőtt
  • Idősebb felnőtt

Egészséges önkénteseket fogad

Nem

Leírás

Inclusion Criteria:

  1. Patients with idiopathic Parkinson's disease diagnosed by two neurologists, according to the Chinese diagnostic criteria for Parkinson's disease formulated in 2020 by the Chinese Parkinson's Disease and Movement Disorders Society based on the MDS Clinical Diagnostic Criteria for Parkinson's disease.
  2. Hoehn and Yahr stage 1-5 in the medication ON state.
  3. Mini-Mental State Examination (MMSE) score >24.
  4. Stable antiparkinsonian medication for at least 1 month before the trial.
  5. No history of orthopedic or musculoskeletal disorders, and no other conditions that may affect balance or gait, such as ophthalmologic disorders.
  6. No history of epilepsy, intracranial tumors, or other neurological disorders; no severe psychiatric disorders, such as schizophrenia; and no long-term use of antipsychotic medications.
  7. Age between 40 and 80 years.
  8. Ability to cooperate with all assessments and eTNS treatment, and provision of written informed consent.

Exclusion Criteria:

  1. Secondary parkinsonism or atypical parkinsonian syndromes.
  2. Current use of anticholinergic medications.
  3. Contraindications to non-invasive electrical neuromodulation.
  4. Previous eTNS treatment within the past 6 months.
  5. Severe neurological, renal, cardiovascular, hepatic, or other major systemic diseases.
  6. Inability to complete clinical assessments or refusal to provide written informed consent.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Crossover kiosztás
  • Maszkolás: Hármas

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Aktív összehasonlító: 40Hz-eTNS
40-Hz eTNS: frequency,40Hz; pulse width, 250 μs; duty cycle, 30 s on/30 s off; total stimulation duration, 20 min.
Eszköz: external Trigeminal Nerve Stimulation, eTNS
The experiment will be conducted in the MED-ON state, consistently 1-2 h after administration of antiparkinsonian medication. Baseline gait and motor function assessments will first be performed, followed by three randomized eTNS stimulation sessions. Gait will be assessed after each stimulation session, and motor function scales will be reassessed after completion of all experimental conditions.
Más nevek:
  • Anti-parkinson's disease drugs
Aktív összehasonlító: 120Hz-eTNS
120-Hz eTNS: frequency,120Hz; pulse width, 250 μs; duty cycle, 30 s on/30 s off; total stimulation duration, 20 min.
Eszköz: external Trigeminal Nerve Stimulation, eTNS
The experiment will be conducted in the MED-ON state, consistently 1-2 h after administration of antiparkinsonian medication. Baseline gait and motor function assessments will first be performed, followed by three randomized eTNS stimulation sessions. Gait will be assessed after each stimulation session, and motor function scales will be reassessed after completion of all experimental conditions.
Más nevek:
  • Anti-parkinson's disease drugs
Sham Comparator: sham-eTNS
Sham eTNS used a double-ramp paradigm with the same parameters as the 120-Hz condition(frequency,120Hz; pulse width, 250 μs; total stimulation duration, 20 min.), but current was delivered only at stimulation onset (0-15 s) and midway through the session (15 s at 10 min).
Eszköz: external Trigeminal Nerve Stimulation, eTNS
The experiment will be conducted in the MED-ON state, consistently 1-2 h after administration of antiparkinsonian medication. Baseline gait and motor function assessments will first be performed, followed by three randomized eTNS stimulation sessions. Gait will be assessed after each stimulation session, and motor function scales will be reassessed after completion of all experimental conditions.
Más nevek:
  • Anti-parkinson's disease drugs

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Dual-Task Cost (DTC)
Időkeret: DTC will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor based gait analysis system.
This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.Dual-task cost will be calculated as: [(single-task gait speed - dual-task gait speed) / single-task gait speed] × 100%.DTC reflects the reduction in walking performance under dual-task conditions relative to single-task conditions. A decrease in DTC after eTNS indicates reduced dual-task interference during walking, suggesting that eTNS may reduce dual-task gait cost in patients with PD.
DTC will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor based gait analysis system.
Mean Gait Speed（m/s）
Időkeret: Mean gait speed will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.

This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.

Mean gait speed will be directly obtained from the IDEEA system, which uses inertial sensors to quantitatively monitor gait during walking tasks in patients with PD.
Mean gait speed will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
Mean Stride Length (m)
Időkeret: Mean stride length will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition. Mean stride length will be directly obtained from the IDEEA system, which uses inertial sensors to quantitatively monitor gait during walking tasks in patients with PD.
Mean stride length will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
stride frequency（steps/min）
Időkeret: It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.Stride frequency will be recorded as directly generated by the IDEEA system.Improvement in stride frequency after eTNS suggests potential improvement in walking rhythm and gait control in patients with PD.
It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
Double-support phase percentage（%）
Időkeret: It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.

This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.Double-support phase percentage will be calculated as: (double-support time / gait cycle time) × 100%.

A higher Double-support phase percentage value generally indicates greater reliance on double-limb support to maintain stability, suggesting more cautious gait, impaired dynamic balance, and increased fall risk. A decrease in double-support phase percentage after eTNS suggests reduced dependence on double-limb support and potential improvement in gait stability and dynamic balance in patients with PD.
It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
gait symmetry index（%）
Időkeret: It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.
This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.The symmetry index will be calculated as: |left-side gait parameter - right-side gait parameter| / [0.5 × (left-side gait parameter + right-side gait parameter)] × 100%.The symmetry index reflects the degree of difference between left- and right-side gait parameters and is used to evaluate bilateral gait symmetry. A higher value indicates greater asymmetry, whereas a lower value indicates better gait symmetry. A decrease in the symmetry index after eTNS suggests improved bilateral gait symmetry in patients with PD.
It will be assessed at baseline and after each randomized eTNS condition during walking tasks, using the IDEEA inertial sensor-based gait analysis system.

Egyéb eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Hoehn and Yahr Scale
Időkeret: The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.

This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.The Hoehn and Yahr scale ranges from 1 to 5 in this study. Higher stages indicate more advanced disease and greater motor disability.

It is a clinical staging system used to assess the overall severity of Parkinson's disease based on the distribution of motor symptoms, postural instability, walking ability, and functional disability. A higher stage indicates more severe disease. A decrease in Hoehn and Yahr scale after eTNS would suggest improvement in overall motor function and disease severity.
The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.
Incidence of eTNS-Related Adverse Reactions [Safety and Tolerability]
Időkeret: Throughout the experimental session, approximately 2.5-3 hours
Adverse reactions related to eTNS will be recorded throughout the experimental session, including local skin numbness, tingling, itching, redness at the electrode site, headache, dizziness, or any other discomfort reported by the participant or observed by the investigator. The number and percentage of participants experiencing eTNS-related adverse reactions will be reported.
Throughout the experimental session, approximately 2.5-3 hours
Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III
Időkeret: The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.

This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.

Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III(MDS-UPDRS III) is a clinician-rated motor examination scale used to assess the severity of motor signs in Parkinson's disease, including rigidity, bradykinesia, tremor, gait, posture, and postural stability. The score ranges from 0 to 132, with each item rated from 0 to 4. Higher scores indicate more severe motor impairment.A decrease in the MDS-UPDRS Part III score after eTNS indicates improvement in motor function.
The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.
Tinetti Gait Assessment
Időkeret: The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.
This is a within-subject study. Instrumented gait parameters and clinical rating scales will be assessed at baseline, followed by eTNS stimulation in randomized order under the 120-Hz, 40-Hz, and sham conditions. After each eTNS condition, instrumented gait parameters will be collected during walking tasks. Clinical rating scales will be additionally assessed after the final stimulation condition.The Tinetti Gait Assessment score ranges from 0 to 12. Higher scores indicate better gait performance and stability.The Tinetti Gait Assessment evaluates gait performance during walking, including gait initiation, step length and height, step symmetry, step continuity, walking path, trunk stability, and walking stance. A lower score indicates poorer gait function and greater gait instability, whereas a higher score indicates better gait function. An increase in the Tinetti Gait Assessment score after eTNS suggests improvement in gait function in patients with PD.
The scale will be administered twice: once at baseline before the experiment and once after completion of all eTNS stimulation conditions and walking tasks, namely at the end of the experiment.

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Zhengli Di

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. június 15.

Elsődleges befejezés (Becsült)

2026. július 15.

A tanulmány befejezése (Becsült)

2026. július 15.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. június 8.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. június 14.

Első közzététel (Tényleges)

2026. június 18.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. június 18.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. június 14.

Utolsó ellenőrzés

2026. június 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Kulcsszavak

További vonatkozó MeSH feltételek

Egyéb vizsgálati azonosító számok

  • LSS-K-2026-012-01

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

NEM

IPD terv leírása

Individual participant data will not be shared because the informed consent documents and ethics approval do not specifically include permission for public or external sharing of individual-level participant data. Aggregate study results may be shared through publications or presentations.

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel